Mylan’s Lantus biosimilar held up by manufacturing issue

PBM cuts insulin co-pay as lawmaker confrontations loom

Express Scripts has announced a plan to cut patient co-pays for insulin products at $25 a month ahead of a pricing showdown with US politicians next week.

One Drop and MannKind team for inhalable insulin trial

Trial to investigate One Drop's diabetes management solution with MannKind's Afrezza.

Oral insulin could still be a reality, says Novo Nordisk

Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market .

Novo hopes hypoglycaemia data will boost Tresiba

Lower severe hypo risk compared with Lantus - but no cardiac benefit.

Lilly and Boehringer biosimilar undercuts Lantus by 15%

Sanofi under pressure following long-awaited biosimilar launch.